Coeurative, Inc. — SEC Form D Filing

Coeurative, Inc. filed an SEC Form D on October 13, 2026, reporting $100K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
October 13, 2026
Amount reported
$100K
Round stage
Pre-Seed
Industry
Pharmaceuticals
Website
https://coeurative.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Millions of patients experience angina pectoris, a condition where the heart does not receive enough oxygen-rich blood, including those with INOCA and refractory angina who still suffer attacks despite existing therapies.

Solution

Coeurative is developing CR-0305, a therapy that harnesses a cellular response to oxygen deficiency to open coronary arteries more effectively, aiming to restore proper blood flow with a dual-mechanism approach.

Verdict

This cleared because it presented a novel mechanism for an undeniable chronic condition with high unmet needs, not because its commercial path or long-term market differentiation were well-defined. Investors were implicitly betting on the early scientific promise of CR-0305 to deliver superior efficacy where existing therapies fail, validating the biological hypothesis. The limited upside stemmed from the early stage, high-risk drug development, where clinical hurdles and the extensive capital requirements for Phase 2/3 trials inherently capped immediate valuation growth.

Source: SEC EDGAR Form D filing